147 related articles for article (PubMed ID: 17437612)
41. Evaluation of patients with multiple sclerosis using a combination of morphometrical features and clinical scores.
Varoğlu AO; Odaci E; Gumus H; Keles ON; Unal B; Deniz O
J Clin Neurosci; 2010 Feb; 17(2):191-5. PubMed ID: 20036126
[TBL] [Abstract][Full Text] [Related]
42. Cigarette smoking and progression in multiple sclerosis.
Koch M; van Harten A; Uyttenboogaart M; De Keyser J
Neurology; 2007 Oct; 69(15):1515-20. PubMed ID: 17923613
[TBL] [Abstract][Full Text] [Related]
43. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
44. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
45. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
[TBL] [Abstract][Full Text] [Related]
46. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
[TBL] [Abstract][Full Text] [Related]
47. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis.
Koch M; Ramsaransing GS; Arutjunyan AV; Stepanov M; Teelken A; Heersema DJ; De Keyser J
J Neurol; 2006 Apr; 253(4):483-7. PubMed ID: 16283096
[TBL] [Abstract][Full Text] [Related]
48. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
49. Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
Choi IY; Lee P; Hughes AJ; Denney DR; Lynch SG
Mult Scler; 2017 Jun; 23(7):956-962. PubMed ID: 27620894
[TBL] [Abstract][Full Text] [Related]
50. Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.
Muris AH; Smolders J; Rolf L; Klinkenberg LJ; van der Linden N; Meex S; Damoiseaux J; Hupperts R
PLoS One; 2016; 11(6):e0156122. PubMed ID: 27276080
[TBL] [Abstract][Full Text] [Related]
51. Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening.
Guan JZ; Guan WP; Maeda T; Guoqing X; GuangZhi W; Makino N
Mol Cell Biochem; 2015 Feb; 400(1-2):183-7. PubMed ID: 25424527
[TBL] [Abstract][Full Text] [Related]
52. Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity.
Ferretti G; Bacchetti T; Principi F; Di Ludovico F; Viti B; Angeleri VA; Danni M; Provinciali L
Mult Scler; 2005 Dec; 11(6):677-82. PubMed ID: 16320727
[TBL] [Abstract][Full Text] [Related]
53. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis.
Manouchehrinia A; Stridh P; Khademi M; Leppert D; Barro C; Michalak Z; Benkert P; Lycke J; Alfredsson L; Kappos L; Piehl F; Olsson T; Kuhle J; Kockum I
Neurology; 2020 Jun; 94(23):e2457-e2467. PubMed ID: 32434867
[TBL] [Abstract][Full Text] [Related]
54. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors.
Hawkins SA; McDonnell GV
J Neurol Neurosurg Psychiatry; 1999 Aug; 67(2):148-52. PubMed ID: 10406979
[TBL] [Abstract][Full Text] [Related]
55. Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
Ferreira KPZ; Oliveira SR; Kallaur AP; Kaimen-Maciel DR; Lozovoy MAB; de Almeida ERD; Morimoto HK; Mezzaroba L; Dichi I; Reiche EMV; Simão ANC
J Neurol Sci; 2017 Feb; 373():236-241. PubMed ID: 28131195
[TBL] [Abstract][Full Text] [Related]
56. Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis.
Zhang Y; Zhou Y; van der Mei IAF; Simpson S; Ponsonby AL; Lucas RM; Tettey P; Charlesworth J; Kostner K; Taylor BV;
J Neurol Neurosurg Psychiatry; 2019 Jun; 90(6):636-641. PubMed ID: 30782980
[TBL] [Abstract][Full Text] [Related]
57. Markers of oxidative/nitrative damage of plasma proteins correlated with EDSS and BDI scores in patients with secondary progressive multiple sclerosis.
Morel A; Bijak M; Niwald M; Miller E; Saluk J
Redox Rep; 2017 Nov; 22(6):547-555. PubMed ID: 28521618
[TBL] [Abstract][Full Text] [Related]
58. Plasma citrulline levels are increased in patients with multiple sclerosis.
Vande Vyver M; Beelen R; De Keyser J; Nagels G; Van Binst AM; Verborgh C; D'haeseleer M
J Neurol Sci; 2018 Apr; 387():174-178. PubMed ID: 29571859
[TBL] [Abstract][Full Text] [Related]
59. Smoking and worsening disability in multiple sclerosis: A meta-analysis.
Heydarpour P; Manouchehrinia A; Beiki O; Mousavi SE; Abdolalizadeh A; -Lakeh MM; Sahraian MA
Acta Neurol Scand; 2018 Jul; 138(1):62-69. PubMed ID: 29542102
[TBL] [Abstract][Full Text] [Related]
60. Serum malondialdehyde as a lipid peroxidation marker in multiple sclerosis patients and its relation to disease characteristics.
Ghonimi NAM; Elsharkawi KA; Khyal DSM; Abdelghani AA
Mult Scler Relat Disord; 2021 Jun; 51():102941. PubMed ID: 33895606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
